ResMed Inc. (RMD): Today's Featured Health Services Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ResMed ( RMD) pushed the Health Services industry lower today making it today's featured Health Services laggard. The industry as a whole closed the day up 0.2%. By the end of trading, ResMed fell $0.54 (-1.1%) to $49.70 on light volume. Throughout the day, 635,329 shares of ResMed exchanged hands as compared to its average daily volume of 1,097,600 shares. The stock ranged in price between $49.51-$50.14 after having opened the day at $50.00 as compared to the previous trading day's close of $50.24. Other companies within the Health Services industry that declined today were: BG Medicine ( BGMD), down 11.3%, ZELTIQ Aesthetics ( ZLTQ), down 6.4%, Misonix ( MSON), down 6.4% and Pingtan Marine Enterprise ( PME), down 6.2%.

ResMed Inc., through its subsidiaries, engages in the development, manufacture, and distribution of medical equipment for treating, diagnosing, and managing sleep-disordered breathing and other respiratory disorders. ResMed has a market cap of $7.1 billion and is part of the health care sector. Shares are up 20.9% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate ResMed a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates ResMed as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, solid stock price performance and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front, Response Genetics ( RGDX), up 14.5%, Cardica ( CRDC), up 10.5%, TearLab Corpoartion ( TEAR), up 8.8% and Arrhythmia Research Technology ( HRT), up 6.5% , were all gainers within the health services industry with PerkinElmer ( PKI) being today's featured health services industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Here's Why This Rally Is Sustainable: Cramer's 'Mad Money' Recap (Tuesday 1/24/17)

ResMed: Cramer's Top Takeaways

Why CarMax and Garmin Could Be Prime Candidates for a Short Squeeze

Why a Massive Short Squeeze Could Send These 4 Stocks Into Orbit

ResMed (RMD) Stock Sharply Lower After Q1 Results Miss Estimates